Mechanisms of the development of pain in chronic venous diseases, including pelvic congestion syndrome, are not studied in detail so far. The existing hypotheses of the occurrence of venous pelvic pain do not allow to answer the question why some patients have no pain syndrome, while others have very pronounced pain despite the same morphofunctional changes in the pelvic veins. This review presents current hypotheses of the venous pelvic pain development, data on some vasoactive neuropeptides (endothelin, calcitonin gene-related peptide, and substance P), their role in the modulation of vascular tone and sensation of pain, and possible association between neurogenic inflammation and venous pelvic pain, as well as provides rationale for studying the activity of these neurotransmitters in the treatment of pelvic congestion syndrome and pelvic pain.
TaylorHC.Vascular congestion and hyperemia; their effect on function and structure in the female reproductive organs. Part I. Am J Obstet Gynecol1949;
57: 211–230.
IgnacioEADuaRSarinS, et al.
Pelvic congestion syndrome: diagnosis and treatment.Semin Intervent Radiol2008;
25: 361–368.
4.
Dos SantosSJHoldstockJMHarrisonCC, et al.
Ovarian vein diameter cannot be used as an indicator of ovarian venous reflux.Eur J Vasc Endovasc Surg2015;
49: 90–94.
5.
GavrilovSGMoskalenkoEPKaralkinAV, et al.
Is the diameter of the pelvic veins a predictor of pelvic venous congestion?Phlebologiya2017;
11: 28–31. [in Russian]
6.
LabordaAMedranoJde BlasI, et al.
Endovascular treatment of pelvic congestion syndrome: visual analog scale (VAS) long-term follow-up clinical evaluation in 202 patients. Cardiovasc Intervent Radiol2013;
36: 1006–1014.
7.
BorghiCDell'AttiL.Pelvic congestion syndrome: the current state of the literature.Arch Gynecol Obstet2016;
293: 291–301.
8.
CheongYCSmotraGWilliamsAC.Non-surgical interventions for the management of chronic pelvic pain. Cochrane Database Syst Rev2014;
3: CD008797.
9.
DanzigerN.Pathophysiology of pain in venous disease.J Mal Vasc2007;
32: 1–7.
10.
McMahonSBKoltzenburgM (eds). Wall and Melzack’s textbook of pain. 5th ed.
London:
Elsevier Churchill Livingstone, 2005, 1239 p.
11.
OmoiguiS.The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 – inflammatory profile of pain syndromes.Med Hypotheses2007;
69: 1169–1178.
12.
DinakarPStillmanAM.Pathogenesis of pain.Semin Pediatr Neurol2016;
23: 201–208.
13.
WebbDJ.Endogenous endothelin generation maintains vascular tone in humans.J Hum Hypertens1995;
9: 459–463
14.
YanagisawaMKuriharaHKimuraS, et al.
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature1988;
332: 411–415.
15.
AguOHamiltonGBakerDM, et al.
Endothelin receptors in the aetiology and pathophysiology of varicose veins.Eur J Vasc Endovasc Surg2002;
23: 165–171.
16.
YangLQiGYCaoYX, et al.
The relationship between endothelin receptors and chronic venous insufficiency of lower extremities. Zhonghua Wai Ke Za Zhi2008;
46: 1325–1328.
17.
GyftopoulosKChondrogianniCPapadakiH.Increased expression of endothelin-1 and its receptors in varicocele: an immunohistochemical study.Fertil Steril2011;
95: 2554–2556.e1–2.
18.
PietrzyckaAKózkaMUrbanekT, et al.
Effect of micronized purified flavonoid fraction therapy on endothelin-1 and TNF-α levels in relation to antioxidant enzyme balance in the peripheral blood of women with varicose veins.Curr Vasc Pharmacol2015;
13: 801–808.
19.
RosenfeldMGMermodJJAmaraSG, et al.
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing.Nature1983;
304: 129–135.
20.
BrainSDGrantAD.Vascular actions of calcitonin gene-related peptide and adrenomedullin.Physiol Rev2004;
84: 903–934.
21.
AubdoolAAKodjiXBrainSD. Calcitonin gene-related peptide (CGRP). In: Michael C (ed) Reference module in biomedical sciences. Netherlands: Elsevier, 2017.
22.
AubdoolAAKodjiXBrainSD. Calcitonin gene-related peptide (CGRP). In: Ilpo H (ed) Encyclopedia of endocrine diseases. 2nd ed. 2017, pp. 204–212.
23.
RaddantACRussoAF.Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med2011;
13: e36.
24.
StonesRWThomasDCBeardRW.Suprasensitivity to calcitonin gene-related peptide but not vasoactive intestinal peptide in women with chronic pelvic pain.Clin Auton Res1992;
2: 343–348.
25.
StonesRW.Chronic pain in women: new perspectives on pathophysiology and management.Reprod Med Rev2000;
8: 229–240
26.
ShawketSDickersonCHazlemanB, et al.
Selective suprasensitivity to calcitonin gene-related peptide in the hands in Raynaud's phenomenon.Lancet1989;
334: 1354–1357.
27.
SmillieS-JBrainSD.Calcitonin gene-related peptide (CGRP) and its role in hypertension.Neuropeptides2011;
45: 93–104.
28.
KeeZKodjiXBrainSD.The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol2018;
9: 1249.
29.
QiaoLYGriderJR.Up-regulation of calcitonin gene-related peptide and receptor tyrosine kinase TrkB in rat bladder afferent neurons following TNBS colitis.Exp Neurol2007;
204: 667–679.
30.
PanXQGonzalezJAChangS, et al.
Experimental colitis triggers the release of substance P and calcitonin gene-related peptide in the urinary bladder via TRPV1 signaling pathways. ExpNeurol2010;
225: 262–273.
31.
MistrovaEKruzliakPChottova DvorakovaM.Role of substance P in the cardiovascular system.Neuropeptides2016;
58: 41–51.
32.
AbdalaAPHaibaraASColombariE.Cardiovascular responses to substance P in the nucleus tractus solitarii: microinjection study in conscious rats.Am J Physiol Heart Circ Physiol2003;
285: H891–H898.
33.
HökfeltTElfvinLGSchultzbergM, et al.
On the occurrence of substance P-containing fibers in sympathetic ganglia: immunohistochemical evidenceBrain Res1977;
132: 29–41.
34.
StonesRWLoeschABeardRW, et al.
Substance P: endothelial localization and pharmacology in the human ovarian vein.Obstet Gynecol1995;
85: 273–278.
35.
OrigoniMLeone Roberti MaggioreUSalvatoreS, et al.
Neurobiological mechanisms of pelvic pain.Biomed Res Int2014; 2014: 903848.
36.
MitsikostasDDReuterU.Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies.Curr Opin Neurol2017;
30: 272–280.
37.
TaskinOSahinLGavrilovSG, et al.
Medical treatment of pelvic congestion syndrome.Phlebolymphology2016;
23: 146–153.
38.
GavrilovSGTurischevaOO.Conservative treatment of pelvic congestion syndrome: indications and opportunities.Curr Med Res Opin2017;
33: 1099–1103.
